www.deltexmedical.com
Deltex Medical manufactures and markets the CardioQ-ODMÔ system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world.
Deltex Medical Group’s CardioQ product selected for US research programme
Deltex Medical Group (LON:DEMG) told investors that it has been picked to take part in a research project in the United States.
Hospitals run by the Premier Healthcare Alliance will trial the firm’s CardioQ oesophageal doppler monitoring device as part of the research programme.
According to Deltex the programme, called the Premier QUEST® Comparative Effectiveness & Innovation Program (QCEIP), helps the American healthcare community better understand patient outcomes associated with the use of certain medical products.
"Being selected to work with Premier on the QUEST Comparative Effectiveness & Innovation Program creates a major opportunity for Deltex Medical,” said chief executive Ewan Phillips
“We expect to be able to demonstrate and then promote the value of CardioQ-ODM within a collaboration of some of the USA's leading hospitals, including some of our existing accounts.
“Success has the potential to accelerate the wide-scale adoption of CardioQ-ODM in the USA."
Deltex says the research programme leverages data from America’s most comprehensive repository of clinical, financial and outcomes information to test, validate and substantiate the concepts put forward by suppliers of new healthcare products.
The Premier Healthcare Alliance aims to improve performance across more than 2,500 American hospitals.



















